EuroBiotech: More Articles of Note

(NS Newsflash/CC BY 2.0)

> Selvita raised $41 million (€33 million). The Polish drug discovery shop will use the cash to support the advance of its pipeline, including CDK8 kinase cancer candidate SEL120. Statement 

> Galapagos and MorphoSys presented phase 1 data on their atopic dermatitis candidate. Five of the six patients who received the highest dose of the IL-17C antibody experienced a 50% improvement on a disease severity index. A phase 2 trial will start in the coming months. Release

> Acacia Pharma set its IPO price range at €3.60 ($4.40) to €4.60 a share. That values the company at up to €180 million. In 2015, Acacia pulled out of an attempt to raise £150 million in a London IPO. Statement (PDF)


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Arix Bioscience extended its reach into China through an agreement with Fosun. The pact gives Arix’s portfolio companies a route into China, while also providing the investor with a source of opportunities in the country. Release 

> Minoryx Therapeutics spun off its site-directed enzyme enhancement therapy platform to create a new company, Gain Therapeutics. The move frees Minoryx to concentrate on a clinical-phase CNS drug while Gain works to squeeze additional assets out the platform. Statement

> Ascendis Pharma priced a stock offering that will net it around $211 million (€172 million). The Danish drug developer will use the money to advance TransCon Growth Hormone toward the market. Release

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.